Secretome-based proteomics reveals sulindac-modulated proteins released from colon cancer cells

Proteomics - Clinical Applications

Volumn 3, Issue 4, 2009, Pages 433-451

  Ji, Hong ^a   Greening, David W ^a   Kapp, Eugene A ^a   Moritz, Robert L ^a   Simpson, Richard J ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Apoptosis; Exosomes; NSAIDs; Secretome; Sulindac

Indexed keywords

BINDING PROTEIN; CALUMENIN; INTERLEUKIN 8; ONCOGENE PROTEIN GRO ALPHA; ONCOPROTEIN; PROFILIN; PROFILIN I; PROTEIN 14 3 3; PROTEIN ALIX; PROTEIN MAC 2; PROTEIN PRECURSOR; SULINDAC; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL PROLIFERATION; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; EXOSOME; HUMAN; HUMAN CELL; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

RODENTIA;

EID: 65549139002     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200800077     Document Type: Article

References (94)

1. Garcea, G., Sharma, R. A., Dennison, A., Steward, W. P. et al., Molecular biomarkers of colorectal carcinogenesis and their role in surveillance and early intervention. Eur. J. Cancer 2003, 39, 1041-1052.
2. Selby, J. V., Friedman, G. D., Quesenberry, C. P., Jr., Weiss, N. S., A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N. Engl. J. Med. 1992, 326, 653-657.
3. Hawk, E. T., Levin, B., Colorectal cancer prevention. J. Clin. Oncol. 2005, 23, 378-391.
4. Thun, M. J., Henley, S. J., Patrono, C., Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst. 2002, 94, 252-266.
5. Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W. et al., A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 2003, 348, 891-899.
6. Benamouzig, R., Deyra, J., Martin, A., Girard, B. et al., Daily soluble aspirin and prevention of colorectal adenoma recurrence: One-year results of the APACC trial. Gastroenterology 2003, 125, 328-336.
7. Bertagnolli, M. M., Eagle, C. J., Zauber, A. G., Redston, M. et al., Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 2006, 355, 873-884.
8. Beazer-Barclay, Y., Levy, D. B., Moser, A. R., Dove, W. F. et al., Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis 1996, 17, 1757-1760.
9. Moorghen, M., Ince, P., Finney, K. J., Sunter, J. P. et al., A protective effect of sulindac against chemically-induced primary colonic tumours in mice. J. Pathol. 1988, 156, 341-347.
10. Skinner, S. A., Penney, A. G., O'Brien, P. E., Sulindac inhibits the rate of growth and appearance of colon tumors in the rat. Arch. Surg. 1991, 126, 1094-1096.
11. Piazza, G. A., Alberts, D. S., Hixson, L. J., Paranka, N. S. et al., Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. 1997, 57, 2909-2915.
12. Rao, C. V., Rivenson, A., Simi, B., Zang, E. et al., Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res. 1995, 55, 1464-1472.
13. Boolbol, S. K., Dannenberg, A. J., Chadburn, A., Martucci, C. et al., Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 1996, 56, 2556-2560.
14. Goldberg, Y., Nassif, I. I., Pittas, A., Tsai, L. L. et al., The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: Alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 1996, 12, 893-901.
15. Bigler, J., Whitton, J., Lampe, J. W., Fosdick, L. et al., CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res. 2001, 61, 3566-3569.
16. Ulrich, C. M., Bigler, J., Potter, J. D., Nonsteroidal anti-inflammatory drugs for cancer prevention: Promise, perils and pharmacogenetics. Nat. Rev. Cancer 2006, 6, 130-140.
17. Martinez, M. E., O'Brien, T. G., Fultz, K. E., Babbar, N. et al., Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc. Natl. Acad. Sci. USA 2003, 100, 7859-7864.
18. Fries, S., Grosser, T., Price, T. S., Lawson, J. A. et al., Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 2006, 130, 55-64.
19. Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A. et al., Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 2005, 352, 1092-1102.
20. Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S. et al., Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 1993, 328, 1313-1316.
21. Steinbach, G., Lynch, P. M., Phillips, R. K., Wallace, M. H. et al., The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 2000, 342, 1946-1952.
22. Gasparini, G., Longo, R., Sarmiento, R., Morabito, A., Inhibitors of cyclo-oxygenase 2: A new class of anticancer agents? Lancet Oncol. 2003, 4, 605-615.
23. Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M. et al., Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107, 1183-1188.
24. Sarraf, P., Mueller, E., Jones, D., King, F. J. et al., Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat. Med. 1998, 4, 1046-1052.
25. Kohno, H., Yoshitani, S., Takashima, S., Okumura, A. et al., Troglitazone, a ligand for peroxisome proliferator-activated receptor gamma, inhibits chemically-induced aberrant crypt foci in rats. Jpn. J. Cancer Res. 2001, 92, 396-403.
26. DuBois, R. N., Gupta, R., Brockman, J., Reddy, B. S. et al., The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carcinogenesis 1998, 19, 49-53.
27. He, T. C., Chan, T. A., Vogelstein, B., Kinzler, K. W., PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999, 99, 335-345.
28. Park, B. H., Vogelstein, B., Kinzler, K. W., Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells. Proc. Natl. Acad. Sci. USA 2001, 98, 2598-2603.
29. Antonakopoulos, N., Karamanolis, D. G., The role of NSAIDs in colon cancer prevention. Hepatogastroenterology 2007, 54, 1694-1700.
30. Simpson, R. J., Jensen, S. S., Lim, J. W. E., Proteomic profiling of exosomes: Current perspectives. Proteomics 2008, 8, 4083-4099.
31. Joyce, J. A., Therapeutic targeting of the tumor micro-environment. Cancer Cell 2005, 7, 513-520.
32. Radisky, D. C., Bissell, M. J., Cancer. Respect thy neighbor! Science 2004, 303, 775-777.
33. Kalluri, R., Zeisberg, M., Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6, 392-401.
34. Minchinton, A. I., Tannock, I. F., Drug penetration in solid tumours. Nat. Rev. Cancer 2006, 6, 583-592.
35. Galon, J., Fridman, W. H., Pages, F., The adaptive immunologic microenvironment in colorectal cancer: A novel perspective. Cancer Res. 2007, 67, 1883-1886.
36. Whitehead, R. H., Macrae, F. A., St John, D. J., Ma, J., A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer. J. Natl. Cancer Inst. 1985, 74, 759-765.
37. Mosmann, T., Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55-63.
38. Ji, H., Moritz, R. L., Kim, Y. S., Zhu, H. J., Simpson, R. J., Analysis of Ras-induced oncogenic transformation of NIH-3T3 cells using differential-display 2-DE proteomics. Electrophoresis 2007, 28, 1997-2008.
39. Perkins, D. N., Pappin, D. J., Creasy, D. M., Cottrell, J. S., Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999, 20, 3551-3567.
40. Bairoch, A., Apweiler, R., Wu, C. H., Barker, W. C. et al., The Universal Protein Resource (UniProt). Nucleic Acids Res. 2005, 33, D154-D159.
41. Hubbard, T., Andrews, D., Caccamo, M., Cameron, G. et al., Ensembl 2005. Nucleic Acids Res. 2005, 33, D447-D453.
42. Moritz, R. L., Clippingdale, A. B., Kapp, E. A., Eddes, J. S. et al., Application of 2-D free-flow electrophoresis/RP-HPLC for proteomic analysis of human plasma depleted of multi high-abundance proteins. Proteomics 2005, 5, 3402-3413.
43. Greening, D. W., Glenister, K. M., Kapp, E. A., Moritz, R. L. et al., Comparison of human platelet membrane-cytoskeletal proteins with the plasma proteome: Towards understanding the platelet-plasma nexus. Proteomics Clin. Appl. 2008, 2, 63-77.
44. Kapp, E. A., Schutz, F., Reid, G. E., Eddes, J. S. et al., Mining a tandem mass spectrometry database to determine the trends and global factors influencing peptide fragmentation. Anal. Chem. 2003, 75, 6251-6264.
45. Ji, H., Baldwin, G. S., Burgess, A. W., Moritz, R. L. et al., Epidermal growth factor induces serine phosphorylation of stathmin in a human colon carcinoma cell line (LIM1215). J. Biol. Chem. 1993, 268, 13396-13405.
46. Parker, A. L., Kadakia, S. C., Maccini, D. M., Cassaday, M. A., Angueira, C. E., Disappearance of duodenal polyps in Gardner's syndrome with sulindac therapy. Am. J. Gastroenterol. 1993, 88, 93-94.
47. Raposo, G., Nijman, H. W., Stoorvogel, W., Liejendekker, R. et al., B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 1996, 183, 1161-1172.
48. Segura, E., Nicco, C., Lombard, B., Veron, P. et al., ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. Blood 2005, 106, 216-223.
49. Skokos, D., Le Panse, S., Villa, I., Rousselle, J. C. et al., Mast cell-dependent B and T lymphocyte activation is mediated by the secretion of immunologically active exosomes. J. Immunol. 2001, 166, 868-876.
50. Unlu, M., Morgan, M. E., Minden, J. S., Difference gel electrophoresis: A single gel method for detecting changes in protein extracts. Electrophoresis 1997, 18, 2071-2077.
51. Lilley, K. S., Razzaq, A., Dupree, P., Two-dimensional gel electrophoresis: Recent advances in sample preparation, detection and quantitation. Curr. Opin. Chem. Biol. 2002, 6, 46-50.
52. Patten, E. J., DeLong, M. J., Effects of sulindac, sulindac metabolites, and aspirin on the activity of detoxification enzymes in HT-29 human colon adenocarcinoma cells. Cancer Lett. 1999, 147, 95-100.
53. Newmark, H. L., Bertagnolli, M. M., Aspirin and colon cancer prevention. Gastroenterology 1998, 115, 1036.
54. Gupta, R. A., DuBois, R. N., Aspirin, NSAIDS, and colon cancer prevention: Mechanisms? Gastroenterology 1998, 114, 1095-1098.
55. Taketo, M. M., Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J. Natl. Cancer Inst. 1998, 90, 1529-1536.
56. Cruz-Correa, M., Hylind, L. M., Romans, K. E., Booker, S. V., Giardiello, F. M., Long-term treatment with sulindac in familial adenomatous polyposis: A prospective cohort study. Gastroenterology 2002, 122, 641-645.
57. Ahn, S.-M., Simpson, R. J., Body fluid proteomics: Prospects for biomarker discovery. Proteomics Clin. Appl. 2007, 1, 1004-1015.
58. Koths, K., Taylor, E., Halenbeck, R., Casipit, C., Wang, A., Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. J. Biol. Chem. 1993, 268, 14245-14249.
59. Iacobelli, S., Arno, E., D'Orazio, A., Coletti, G., Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res. 1986, 46, 3005-3010.
60. Iacobelli, S., Sismondi, P., Giai, M., D'Egidio, M. et al., Prognostic value of a novel circulating serum 90K antigen in breast cancer. Br. J. Cancer 1994, 69, 172-176.
61. Ullrich, A., Sures, I., D'Egidio, M., Jallal, B. et al., The secreted tumor-associated antigen 90K is a potent immune stimulator. J. Biol. Chem. 1994, 269, 18401-18407.
62. Marchetti, A., Tinari, N., Buttitta, F., Chella, A. et al., Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I nonsmall cell lung cancer patients. Cancer Res. 2002, 62, 2535-2539.
63. Ulmer, T. A., Keeler, V., Loh, L., Chibbar, R. et al., Tumor-associated antigen 90K/Mac-2-binding protein: Possible role in colon cancer. J. Cell Biochem. 2006, 98, 1351-1366.
64. Bair, E. L., Nagle, R. B., Ulmer, T. A., Laferte, S., Bowden, G. T., 90K/ Mac-2 binding protein is expressed in prostate cancer and induces promatrilysin expression. Prostate 2006, 66, 283-293.
65. Fornarini, B., D'Ambrosio, C., Natoli, C., Tinari, N. et al., Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. Blood 2000, 96, 3282-3285.
66. Sasaki, T., Brakebusch, C., Engel, J., Timpl, R., Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin. EMBO J. 1998, 17, 1606-1613.
67. Grossmann, J., Molecular mechanisms of "detachment-induced apoptosis-Anoikis". Apoptosis 2002, 7, 247-260.
68. Valentijn, A. J., Zouq, N., Gilmore, A. P., Anoikis. Biochem. Soc. Trans. 2004, 32, 421-425.
69. Trioulier, Y., Torch, S., Blot, B., Cristina, N. et al., Alix, a protein regulating endosomal trafficking, is involved in neuronal death. J. Biol. Chem. 2004, 279, 2046-2052.
70. Thery, C., Boussac, M., Veron, P., Ricciardi-Castagnoli, P. et al., Proteomic analysis of dendritic cell-derived exosomes: A secreted subcellular compartment distinct from apoptotic vesicles. J. Immunol. 2001, 166, 7309-7318.
71. Garin, J., Diez, R., Kieffer, S., Dermine, J. F. et al., The phagosome proteome: Insight into phagosome functions. J. Cell Biol. 2001, 152, 165-180.
72. Babst, M., A protein's final ESCRT. Traffic (Copenhagen, Denmark) 2005, 6, 2-9.
73. Missotten, M., Nichols, A., Rieger, K., Sadoul, R., Alix, a novel mouse protein undergoing calcium-dependent interaction with the apoptosis-linked-gene 2 (ALG-2) protein. Cell Death Differ. 1999, 6, 124-129.
74. Wu, Y., Pan, S., Luo, W., Lin, S. H., Kuang, J., Hp95 promotes anoikis and inhibits tumorigenicity of HeLa cells. Oncogene 2002, 21, 6801-6808.
75. Wu, Y., Pan, S., Che, S., He, G. et al., Overexpression of Hp95 induces G1 phase arrest in confluent HeLa cells. Differentiation 2001, 67, 139-153.
76. Feldner, J. C., Brandt, B. H., Cancer cell motility - On the road from c-erbB-2 receptor steered signaling to actin reorganization. Exp. Cell Res. 2002, 272, 93-108.
77. Witke, W., The role of profilin complexes in cell motility and other cellular processes. Trends Cell Biol. 2004, 14, 461-469.
78. Janke, J., Schluter, K., Jandrig, B., Theile, M. et al., Suppression of tumorigenicity in breast cancer cells by the microfilament protein profilin 1. J. Exp. Med. 2000, 191, 1675-1686.
79. Hermeking, H., The 14-3-3 cancer connection. Nat. Rev. Cancer 2003, 3, 931-943.
80. Rosenquist, M., 14-3-3 proteins in apoptosis. Braz. J. Med. Biol. Res. 2003, 36, 403-408.
81. Won, J., Kim, D. Y., La, M., Kim, D. et al., Cleavage of 14-3-3 protein by caspase-3 facilitates bad interaction with Bcl-x(L) during apoptosis. J. Biol. Chem. 2003, 278, 19347-19351.
82. Nufer, O., Hauri, H. P., ER export: Call 14-3-3. Curr. Biol. 2003, 13, R391-R393.
83. Liou, J. Y., Ghelani, D., Yeh, S., Wu, K. K., Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3epsilon. Cancer Res. 2007, 67, 3185-3191.
84. Honore, B., Vorum, H., The CREC family, a novel family of multiple EF-hand, low-affinity Ca(2+)-binding proteins localised to the secretory pathway of mammalian cells. FEBS Lett. 2000, 466, 11-18.
85. Scherer, P. E., Lederkremer, G. Z., Williams, S., Fogliano, M. et al., Cab45, a novel (Ca2+)-binding protein localized to the Golgi lumen. J. Cell Biol. 1996, 133, 257-268.
86. Vorum, H., Hager, H., Christensen, B. M., Nielsen, S., Honore, B., Human calumenin localizes to the secretory pathway and is secreted to the medium. Exp. Cell Res. 1999, 248, 473-481.
87. Berridge, M. J., Bootman, M. D., Lipp, P., Calcium - A life and death signal. Nature 1998, 395, 645-648.
88. Weiss, H., Amberger, A., Widschwendter, M., Margreiter, R. et al., Inhibition of store-operated calcium entry contributes to the anti-proliferative effect of nonsteroidal anti-inflammatory drugs in human colon cancer cells. Int. J. Cancer 2001, 92, 877-882.
89. Frederick, M. J., Clayman, G. L., Chemokines in cancer. Expert Rev. Mol. Med. 2001, 2001, 1-18.
90. Brew, R., Southern, S. A., Flanagan, B. F., McDicken, I. W., Christmas, S. E., Detection of interleukin-8 mRNA and protein in human colorectal carcinoma cells. Eur. J. Cancer 1996, 32A, 2142-2147.
91. Richmond, A., Balentien, E., Thomas, H. G., Flaggs, G. et al., Molecular characterization and chromosomal mapping of melanoma growth stimulatory activity, a growth factor structurally related to beta-thromboglobulin. EMBO J. 1988, 7, 2025-2033.
92. Fujisawa, N., Sakao, Y., Hayashi, S., Hadden, W. A., III et al., alpha-Chemokine growth factors for adenocarcinomas: A synthetic peptide inhibitor for alpha-chemokines inhibits the growth of adenocarcinoma cell lines. J. Cancer Res. Clin. Oncol. 2000, 126, 19-26.
93. Housby, J. N., Cahill, C. M., Chu, B., Prevelige, R. et al., Nonsteroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes. Cytokine 1999, 11, 347-358.
94. Takehara, H., Iwamoto, J., Mizokami, Y., Takahashi, K. et al., Involvement of cyclooxygenase-2-Prostaglandin E2 pathway in interleukin-8 production in gastric cancer cells. Dig. Dis. Sci. 2006, 51, 2188-2197.